Evotec AG (ETR:EVT) has been given a €16.00 ($18.82) price objective by Deutsche Bank AG in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the stock.

Separately, Berenberg Bank set a €9.50 ($11.18) price target on Evotec AG and gave the stock a “buy” rating in a report on Monday, May 29th.

Shares of Evotec AG (EVT) opened at 12.485 on Monday. Evotec AG has a 52 week low of €4.06 and a 52 week high of €14.65. The company has a 50 day moving average price of €13.39 and a 200 day moving average price of €10.47. The company has a market cap of €1.74 billion and a PE ratio of 49.348.

ILLEGAL ACTIVITY WARNING: “Deutsche Bank AG Reiterates €16.00 Price Target for Evotec AG (ETR:EVT)” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/07/deutsche-bank-ag-reiterates-16-00-price-target-for-evotec-ag-etrevt.html.

About Evotec AG

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.